| EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex | lung, |
| melatonin inhibits cell proliferation and induces apoptosis in MDA-MB-361 breast cancer cells in vitro by simultaneously suppressing the COX-2/PGE2, p300/NF-kappaB, and PI3K/Akt/signaling and activating the Apaf-1/caspase-dependent apoptotic pathway. | breast, |
| The dark side of the moon: AKT as a tumor suppressor in the liver? | liver, |
| PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. | None |
| Rapid communication: Microsatellites isolated from BAC clones containing v-akt1 murine thymoma viral oncogene homolog 1 and bradykinin receptor B2 assigned to sheep chromosome 18 by linkage analysis. | thymoma, |
| Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. | glioblastoma, |
| Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. | thyroid, |
| Role for Akt/protein kinase B and activator protein-1 in cellular proliferation induced by the human T-cell leukemia virus type 1 tax oncoprotein. | leukemia, |
| Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. | breast, |
| The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. | colorectal, |
| activation of the PI3K-Akt pathway during liver oncogenesis may be at least partially responsible for the elimination of HBV replication from tumor cells | liver, |
| in most primary brain tumors, AKT is activated by molecular mechanisms other than oncogenic G49A mutations of AKT1 | brain, |
| Absence of mutations in the AKT1 oncogene in glioblastomas and medulloblastomas. | medulloblastomas,glioblastoma, |
| Editorial comment on: Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. | kidney, |
| Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. | kidney, |
| These data provide evidence that, although AKT1 mutations are apparently rare in lung cancer (1.9%), the oncogenic properties of E17K-AKT1 may contribute to the development of a fraction of lung carcinoma with squamous histotype (5.5%). | lung, |
| Proteins such as caveolin-1 (CAV-1) and Akt, Proto-Oncogene Protein, which are known to be altered in colon cancer, affect KLK6 expression and KLK6 secretion | colorectal, |
| Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells. | colorectal, |
| Analysis of oncogenic AKT1 p.E17K mutation in carcinomas of the biliary tract and liver. | liver, |
| inactivation of GRP78 may represent a previously undescribed approach to stop prostate cancer and potentially other cancers resulting from the loss of PTEN tumor suppression and/or activation of the oncogenic AKT | prostate, |